Serova

Serova is an early-stage UK company building a personalised cancer vaccine platform that redesigns the vaccine as the tumour evolves. Its approach uses longitudinal, multi-site tumour data to select tumour-driving mutations and design patient-specific vaccines that reflect the disease state at the time of dosing, and the work is preclinical with limited public disclosure beyond company profiles. OnCo links it to personalised neoantigen mRNA vaccines and to the neoantigen term. Whether re-targeting a vaccine to a moving tumour can be done fast enough to matter clinically is the open question, and the company has published little that would let a reader judge. The personalised vaccine technology page carries the field's evidence.